Related Experiment Video
Updated: Apr 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update
Robert G Hart1, John W Eikelboom1
1McMaster University/Population Health Research Institute, Hamilton Health Sciences, Hamilton, Canada.
Insights
Atrial fibrillation increases stroke risk in the elderly, especially women, due to blood clots. Anticoagulant therapy, like warfarin, significantly reduces this ischemic stroke risk, as shown by decades of research and updated guidelines.
Area of Science:
- Cardiology
- Neurology
- Geriatrics
Background:
- Atrial fibrillation is a prevalent condition linked to disabling strokes in older adults.
- Embolism from left atrial appendage thrombi is a primary mechanism for stroke in atrial fibrillation.
- Early randomized trials demonstrated warfarin's efficacy in reducing ischemic stroke.
Purpose of the Study:
- To review advancements in stroke prevention strategies for atrial fibrillation.
- To discuss key findings from the American Academy of Neurology's guideline update on atrial fibrillation management.
Main Methods:
- Analysis of over 40 randomized clinical trials conducted over 25 years.
- Review of evidence-based guideline updates from the American Academy of Neurology.
Main Results:
- Significant progress has been made in refining stroke prophylaxis for atrial fibrillation patients.
- Anticoagulant therapy has been established as a cornerstone for stroke risk reduction.
Conclusions:
- Stroke prevention in atrial fibrillation has seen remarkable advancements.
- Updated guidelines reflect the cumulative evidence from extensive clinical trials.
Abstract:
Atrial fibrillation is a common, potentially preventable cause of disabling stroke in the elderly, particularly in elderly women, resulting from embolism of stasis-precipitated thrombi formed in the left atrial appendage. In 1989, the first randomized clinical trial of anticoagulant therapy in atrial fibrillation showed that warfarin produced a large reduction in ischemic stroke.1 In the ensuing 25 years, more than 40 additional randomized trials have permitted stroke prophylaxis to be importantly refined. It has been a period of remarkable progress in stroke prevention. Here, we discuss selected aspects of the American Academy of Neurology (AAN)'s evidence-based guideline update.2.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis IV: Nursing Management
Atherosclerosis III: Management
Dysrhythmias VI: Management of Dysrhythmias
Anticoagulant Drugs: Low-Molecular-Weight Heparins

